



RESEARCH OPPORTUNITY

NAMI is committed to ensuring that the most effective treatments for mental illness are available to those who need them. Determining which treatments are most effective requires research.

When NAMI learns of new studies by physicians and other scientists involving new treatment methods, such as psychotherapies, medications, methods of medication delivery, etc. we become excited. That excitement comes from knowing that scientists continue to learn more about mental illness and look for ways to improve the lives of those affected by it. When NAMI is approached to be involved in research of any type, at any level, we take it very seriously. NAMI's Chief Medical Officer Dr. Ken Duckworth and National Director of Research and Quality Assurance Dr. Teri Brister thoroughly review the research protocols and methodology and the documentation that the study has been approved an Institutional Review Board (IRB) to assure the safety of those involved.

NAMI does not accept financial compensation for recruiting clinical trial participants. NAMI also does not endorse any products or treatments. We share these research opportunity notices with you, our field leaders, to distribute at your discretion if you believe that members of your community may be interested in participating in these trials.

If you have questions about research at NAMI, please visit [NAMI.org/research](https://www.nami.org/research) or email us at research@nami.org.

WHAT IS THE STUDY?

Transcranial magnetic stimulation (TMS) is a non-invasive procedure that uses a magnet to activate specific areas of the brain. TMS may be used to address symptoms of various mental health conditions. This study is a clinical trial seeking to improve the speed and effectiveness of TMS to treat symptoms of psychosis. The goal of this study is to better understand the use of TMS for psychosis and to improve non-medication treatment options for individuals with psychotic disorders. Participation includes clinical interviews, cognitive testing, one week of TMS treatment sessions, and follow-up assessments. Participants will be compensated up to \$1600.

WHO CAN PARTICIPATE?

Individuals may be eligible for this study if they:

- Are 18 to 65 years old
- Have a psychotic disorder, such as schizophrenia or schizoaffective disorder, or are at high risk of developing a psychotic disorder
 - Individuals are especially encouraged to apply if they experience difficulty with the following: engaging in or enjoying activities and social events, organizing their thoughts, or thinking clearly

The researchers are seeking 20 participants for this study.

WHERE IS THE STUDY TAKING PLACE?

This study takes place at Beth Israel Deaconess Medical Center in Boston, Massachusetts. Follow-up assessments may be completed virtually but changes to compensation will apply.

HOW DO I LEARN MORE?

The attached documents have additional information about the study. If you have questions or would like more information, please contact Adam Beermann at (617) 632-7956 or abeerman@bidmc.harvard.edu. You may also complete a free, confidential screening survey here: <https://redcap.bidmc.harvard.edu/redcap/surveys/?s=CPRDLCLC8J>